Differential effects of cyclooxygenase inhibitors on haloperidol-induced catalepsy

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 26, Issue 5, 2002, Pages 819-822

  Naidu, Pattipati S ^a   Kulkarni, Shrinivas K ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

Catalepsy; COX 1; COX 2; Cyclooxygenase; Dopamine; Haloperidol; Prostaglandins

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; HALOPERIDOL; NAPROXEN; NIMESULIDE; PROSTAGLANDIN SYNTHASE INHIBITOR; ROFECOXIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CATALEPSY; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFECT; DRUG SELECTIVITY; MALE; MOUSE; NONHUMAN;

ANIMALS; CATALEPSY; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; HALOPERIDOL; ISOENZYMES; MALE; MEMBRANE PROTEINS; MICE; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES;

EID: 0036592439     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0278-5846(01)00289-5     Document Type: Article

References (19)

1. Ahtee L., Kaariainen I. The role of dopamine in pilocarpine-induced catalepsy. Naunyn-Schimiedeberg's Arch. Pharmacol. 284:1974;25-38.
2. Breder C.D., Dewitt D., Kraig R.P. Characterization of inducible cyclooxygenase in rat brain. J. Comp. Neurol. 355:1995;19-24.
3. Brus R., Herman Z.S., Szkilnik R., Zabawska J. Mediation of central prostaglandin effects by serotonergic neurons. Psychopharmacology. 64:1979;116-120.
4. 2) in rats. Pol. J. Pharmacol. Pharm. 33:1981;467-474.
5. Costall B., Fortune D.H., Naylor R.J., Marsden C.D., Pycock C.J. Serotonergic involvement with neuroleptic catalepsy. Neuropharmacology. 14:1975;859-868.
6. Herman Z.S., Slominsk-Zurek J., Kryk A., Kmieciak-Kolada K. Potentiation of cataleptogenic effects of neuroleptics by prostaglandins. Pol. J. Pharmacol. Pharm. 30:1978;639-646.
7. Hla T., Bishop-Bailey D., Liu C.H., Schaefers H.J., Trifan O.C. Cyclooxygenase-1 and -2 isoenzymes. Int. J. Biochem. Cell Biol. 31:1999;551-557.
8. Hornyckiewicz O. Dopamine in the basal ganglia. Its role and therapeutic implications (including the clinical use of L-DOPA). Br. Med. Bull. 29:1973;172-178.
9. Horrobin D.F., Ally A.I., Karmali R.A. Prostaglandins and schizophrenia: further discussion of the evidence. Psychol. Med. 8:1978;43.
10. Kulkarni S.K., Jain N.K., Singh A. Cyclooxygenase isoenzymes and newer therapeutic potential for selective COX-2 inhibitors. Methods Find. Exp. Clin. Pharmacol. 22:2000;291-298.
11. Lall S.B., Tekur U., Sen P. Effect of drugs influencing synthesis of prostaglandins on haloperidol-induced catalepsy in rats. Ind. J. Physiol. Pharmacol. 28:1984;219-222.
12. 2A/C antagonist, reverse haloperidol-induced catalepsy in rats independently of striatal dopamine release. Psychopharmacology. 131:1997;57-63.
13. Mtabaji J.P., Manku M.S., Horribin D.F. Vascular actions of furosemide and bumetamide on the rat superior mesenteric vascular bed: interactions with prolactin and prostaglandins. Can. J. Physiol. Pharmacol. 64:1976;357-366.
14. 2 in the rat brain, spinal cord and pituitary: basal level and regional distribution. Life Sci. 31:1982;2093-2103.
15. Neal-Beliveau B.S., Joyce J.N., Lucki I. Serotonergic involvement in haloperidol-induced catalepsy. J. Pharmacol. Exp. Ther. 265:1993;207-217.
16. Ono N., Saito R., Abiru T., Kamiya H., Furukawa T. Possible involvement of prostaglandins in cataleptic behaviour in rats. Pharmacol., Biochem. Behav. 25:1986;463-467.
17. Ono N., Abiru T., Sugiyama K., Kamiya H. Influence of cyclooxygenase inhibitors on the cataleptic behaviour induced by haloperidol in mice. Prostaglandins, Leukotrienes Essent. Fatty Acids. 46:1992;59-63.
18. 2 in cardiovascular function in rat. Brain Res. 330:1985;167-169.
19. Yerragani V.K., Chaitin P. A prostaglandin theory of neuroleptic malignant syndrome. Med. Hypotheses. 24:1987;143-149.